

Antiviral Medication – Medical Directive

Medical Advisory Committee Approved: 24OCT2019

Harmonized this document may not reflect the current, electronic version on Lakeridge Health's Intranet, 'The Wave.' Any copies of this document appearing in paper form should ALWAYS be checked against the electronic version prior to use.

Authorizing Prescriber(s)

Physician(s) for the Occupational Health, Safety and Healthy Workplace Department (herein after referred to as Occupational Health (OH)) of Lakeridge Health (LH).

Authorized to Whom

Registered Nurses working in Occupational Health (OHN)

Patient Description/Population

Any Lakeridge Health Colleague (LHC) over the age of 14 who is working on a hospital patient care unit declared to be in outbreak for influenza.

LHCs include:

- employees,
- privileged staff (physicians, dentists, midwives),
- volunteers,
- contract workers, and
- students

Order and/or Procedure

- Provide the LHC with information regarding antiviral medication found on the consent form and information sheet
- Review the consent form to ensure that it has been read, understood and signed
- Perform a brief assessment of relevant allergy status, present health and present medications
- Explain the procedure for taking daily prophylaxis
- Explain the risks, side effects, and precautions found on the consent form
- Ensure there are no contraindications to the medications identified
- Advise the LHC to notify OH of significant side effects
- Provide LHC with prescription for Oseltamivir 75 mg, one capsule per day by mouth for 10 days (e.g. at LHAP), OR
- Dispense Oseltamivir 75 mg capsules, one capsule once a day by mouth for 10 days. (e.g. At LHO, LHB, LHW, LHPP)

Document Sponsor/Owner Group: Occupational Health, Date Approved 24OCT2019

This material has been prepared solely for the use at Lakeridge Health. Lakeridge Health accepts no responsibility for use of this material by any person or organization not associated with Lakeridge Health. No part of this document may be reproduced in any form for publication without the permission of Lakeridge Health.



A printed copy of this document may not reflect the current, electronic version on Lakeridge Health's Intranet, 'The Wave.' Any copies of this document appearing in paper form should ALWAYS be checked against the electronic version prior to use.

Indications to the Implementation of the Directive

The LHC receiving prophylaxis by the OHN:

- is not able to show proof of current seasonal influenza vaccination, or
- is able to show proof of current seasonal influenza vaccination but local Public Health Authority Durham Region Health Department deems the vaccine ineffective with the circulating influenza strain associated with the outbreak.

Contraindications to the Implementation of the Directive

- LHCs with known allergy to Oseltamivir, its ingredients or similar anti-viral drug
- LHCs with known history of kidney disease or known to be pregnant or breastfeeding.
- Consent form not reviewed/signed.

Consent

Written or electronic, voluntary consent completed by the LHC using the form titled *Consent for the Administration of Oseltamivir* after all questions regarding risks, benefits and contraindications have been answered to the satisfaction of the LHC. The consent form may be paper or electronic and must be fully completed and retained in the electronic health record

Documentation Requirements

The discussion and consent process will be documented in the LHCs electronic OH record.

Document prescription for Oseltamivir provided or 10 tablets of 75 mg Oseltamivir dispensed as per Administration of Antiviral Prophylactic Medication during Influenza Outbreak medical directive in OH record.

Review/Evaluation Process

This medical directive will be reviewed every two years, by Occupational Health.

References

OHA/OMA Communicable Disease Surveillance Protocols regarding Influenza Surveillance. Product monograph Oseltamivir